Summit Therapeutics plc Summit Therapeutics Plc : Notice Of Agm

 
TIDMSUMM 
 
 
   Summit Therapeutics plc 
 
   ("Summit" or the "Company") 
 
   PUBLICATION OF UK ANNUAL REPORT 2016/17 AND NOTICE OF ANNUAL GENERAL 
MEETING 
 
   Oxford, UK, 25 April 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: 
SMMT), the drug discovery and development company advancing therapies 
for Duchenne muscular dystrophy and Clostridium difficile infection, 
announces that its Annual Report and Accounts for the year ended 31 
January 2017, together with the Notice of Annual General Meeting have 
today been sent to shareholders. Copies of both documents are available 
on the Company's website, www.summitplc.com. 
 
   The Annual General Meeting will be held at 11:00am BST on Tuesday, 18 
July 2017 at the Milton Park Innovation Centre, 99 Park Drive, Abingdon, 
Oxfordshire, OX14 4RY, UK. 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease, Duchenne 
muscular dystrophy, and the infectious disease, Clostridium difficile 
infection. Further information is available at www.summitplc.com and 
Summit can be followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
Summit Therapeutics 
 Glyn Edwards / Richard Pye (UK office)         Tel: [phone] 
 Erik Ostrowski / Michelle Avery (US office)    [phone] 
Cairn Financial Advisers LLP 
 (Nominated Adviser)                            Tel: [phone] 
 Liam Murray / Tony Rawlinson 
N+1 Singer 
 (Broker)                                       Tel: [phone] 
 Aubrey Powell / Lauren Kettle 
MacDougall Biomedical Communications 
 (US media contact)                            Tel: [phone] 
 Karen Sharma                                  [e-mail] 
Consilium Strategic Communications 
 (Financial public relations, UK)              Tel: [phone] 
 Mary-Jane Elliott / Sue Stuart /              [e-mail] 
 Jessica Hodgson / Lindsey Neville 
 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

April 25, 2017 02:00 ET (06:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.